<DOC>
	<DOCNO>NCT00095121</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety adefovir dipivoxil treatment chronic hepatitis B child adolescent ( age 2 less 18 year ) follow 48 week placebo-controlled , double-blind treatment follow additional 192 week open-label adefovir dipivoxil treatment .</brief_summary>
	<brief_title>Safety Efficacy Adefovir Dipivoxil Children Adolescents With Chronic Hepatitis B</brief_title>
	<detailed_description>Weeks 1 48 ( Study Year 1 ) : The first 48 week study randomize , double-blind , placebo-controlled , parallel-group treatment period . Participants randomly assign treatment 2:1 fashion ADV PLB . Prior randomization , eligible participant classify 1 6 stratum base upon age screening ( 2 &lt; 7 year ; &gt; = 7 &lt; 12 year ; &gt; = 12 &lt; 18 year ) prior exposure treatment chronic hepatitis B ( CHB ) ( prior treatment ; prior treatment ) . Weeks 49 240 ( Study Years 2 5 ) : At Week 48 , placebo-treated participant exhibit HBeAg hepatitis B surface antigen ( HBsAg ) seroconversion Week 44 , plus ADV-treated participant , offer opportunity receive open-label ADV additional 192 week . Any participant HBV DNA &gt; = 1000 copies/mL 2 consecutive visit 12 week apart discontinue open-label study treatment . The exception participant adolescent age range prior lamivudine experience allow opportunity add lamivudine ADV ; similarly , combination fail impart suppression HBV DNA 1000 copies/mL ( confirm ) discontinuation necessary . All participant discontinue study drug due confirm seroconversion request continue return study visit remainder study order evaluate durability seroconversion . Participants wish discontinue study treatment withdraw study prior study completion request return every 4 week 16 week posttreatment evaluation follow early termination visit . Any participant experienced posttreatment hepatic flare 16-week follow-up period follow every 4 week ALT level return &lt; = 2 time upper limit normal ( ULN ) maximum off-treatment follow-up 6 month . Participants experience severe hepatic flare ( per protocol definition ) discontinuation ADV open-label treatment period may eligible receive ADV treatment hepatic flare ( consultation Gilead medical monitor ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Key Positive HBsAg &gt; = 6 month prior randomization positive HBeAg screening . Serum HBV DNA great equal 1 x 100,000 copies/mL ( PCR assay ) initial confirmatory screen visit . Serum ALT level great equal 1.5 x ULN initial confirmatory screen visit . Compensated liver disease anticipate survival great 12 month follow laboratory clinical parameter within 4 week baseline : *Prothrombin time le equal 1 second normal range . *Total bilirubin le 1.3 mg/dL normal direct bilirubin . *Serum albumin great 3 g/dL ( great 30 g/L ) . *No clinical history ascites , variceal bleeding , encephalopathy splenomegaly . *Adequate renal function define creatinine clearance great equal 80 mL/min ( calculate use Schwartz Formula ) . Key Received immunoglobulin , interferon lamivudine therapy within 6 month prior initial screen visit . Participated investigational trial investigational compound within 2 month prior initial screening . Organ bone marrow transplant recipient . Clinical evidence decompensated liver disease . A ChildPughTurcotte score great 6 . Inability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Children</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Adefovir Dipivoxil</keyword>
</DOC>